13 April 2022
Sygnature Discovery have been announced as Partnering Sponsor of the 18th Annual Anglonordic Life Science Conference.
About Sygnature Discovery
Sygnature Discovery is a world-leading integrated drug discovery and non-clinical solutions provider, offering expertise across a broad range of therapeutic areas and biological target classes.
The battle against disease, and the pioneering mission to improve life and health, should be at the top of the agenda for every society. And early drug discovery is right at the heart of this challenge.
It’s a challenge our scientists have been meeting for decades. For us, our work is powered not just by our love of science, but by the value of what we produce. This work is about people. It’s about giving them a better and a longer life. And that is a powerful motivator for success.
Sygnature Discovery’s particular success in this field is due to a distinctive synergy of chemistry, bioscience, drug metabolism and pharmacokinetics, computational design, and in vivo pharmacology. Our unique approach to laboratory working – with multiple disciplines co-located on the same research site in the same laboratories – is key to our success in advancing our customers’ drug discovery projects into clinical development. When hurdles inevitably arise, we bring together different minds and skill sets to create the spark of innovation we need to overcome them.
This is why drug sponsors know they can turn to us with their hopes and their challenges. From target discovery all the way through to preclinical research, Sygnature has the right approach, the right team, and the right tools to enable success.